跳至主要内容
临床试验/jRCT2071220057
jRCT2071220057已完成不适用

A phase I open-label study to investigate the absorption, metabolism and excretion of [14C]KDT-3594 following single oral administration in healthy adult male subjects

Kissei Pharmaceutical Co., Ltd.0 个研究点目标入组 8 人开始时间: 2022年11月8日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
8
主要终点
Urinary radioactivity excretion

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 45age old under(—)
性别
Male

入选标准

  • Healthy Japanese male
  • Age: >18 to =<45 years old
  • BMI: >=18.5 to <25.0 kg/m2
  • Body weight: >=50 kg

排除标准

  • Subjects with complication or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, (including alcoholic liver disease, non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary liver disease), psychiatric, neurological, or allergic disease (including drug allergy, but excluding untreated, asymptomatic or seasonal allergy at the time of administration)

结局指标

主要结局

Urinary radioactivity excretion

放射性物质在尿液中的排泄量

Urinary radioactivity excretion rate

放射性物质在尿液中的排泄速率

Fecal radioactivity excretion

放射性物质在粪便中的排泄量

Fecal radioactivity excretion rate

放射性物质在粪便中的排泄速率

Cumulative excretion

放射性物质的累积排泄量

Cumulative excretion rate

放射性物质的累积排泄速率

Recovery

放射性物质的回收量

Recovery rate

放射性物质的回收速率

Total recovery

放射性物质的总回收量

Total recovery rate

放射性物质的总回收速率

次要结局

  • Radioactivity concentration in whole blood and plasma
  • Concentration of unchanged drug and main metabolites in plasma
  • Metabolite profiling and structural estimation of metabolites in plasma, urine and feces
  • Incidence of adverse events and adverse drug reactions
  • Laboratory tests, vital signs, body weight, 12-lead ECG

研究者

相似试验